|
|
|
News
|
CardioDex Ltd.
|
|
01/05/2012
|
|
New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy
|
|
|
Gamida Cell Ltd.
|
|
13/02/2012
|
|
The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemEx®, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma.
The results of the StemEx study are expected during the second half of 2012
|
|
|
D-Pharm Ltd.
|
|
10/01/2012
|
|
D Pharm expands Chinese cooperation agreement. The agreement with Wanbang Biopharmaceuticals was extended to a new formulation of D Pharm's treatment for ischemic stroke.
|
|
|
D-Pharm Ltd.
|
|
31/10/2011
|
|
D-Pharm announces expected date of interim report for the DP-b99 Acute Ischemic Stroke Study, MACSI
|
|
|
OrSense Ltd.
|
|
20/10/2011
|
|
OrSense's Non-Invasive Hemoglobin Measurement System for Pre-Donation Screening of Anemia Delivers Superior Clinical Value Compared to Current Methods
|
|
|
Gamida Cell Ltd.
|
|
12/07/2011
|
|
The Gamida Cell-Teva Joint Venture Receives Green Light From the Data Monitoring Committee to Continue the Phase III Study of StemEx®, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
|
|
|
D-Pharm Ltd.
|
|
14/06/2011
|
|
DP-b99 Phase III MACSI Study Protocol Published in International Journal of Stroke
|
|
|
OrSense Ltd.
|
|
14/06/2011
|
|
OrSense`s Non Invasive Hemoglobin Monitor has the Potential to Enhance Recruitment of Blood Donors
|
|
|
OrSense Ltd.
|
|
02/05/2011
|
|
OrSense Closes U.S. $18 Million Private Financing to Accelerate Commercialization of Its Non-Invasive Monitoring Products
|
|
|
D-Pharm Ltd.
|
|
14/04/2011
|
|
D-Pharm receives Fast Track designation from FDA for DP-b99 stroke
|
|
|
|
|